Press release
Primary Biliary Cholangitis Treatment Market Valued at USD 1.2 Billion in 2023; Projected to Grow Significantly Through 2034 Driven by Anticipated Pipeline Drugs | DelveInsight
Primary Biliary Cholangitis Market Insight, Epidemiology, and Market Forecast – 2034
DelveInsight's "Primary Biliary Cholangitis Market Insight, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers comprehensive insights into the PBC market, including historical and forecasted epidemiology as well as market trends across the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
The primary biliary cholangitis market size was USD 1.2 billion across the 7MM in 2023, which is forecasted to increase steadily from 2024 to 2034. Furthermore, the US accounted for the largest PBC market share. This trend is expected to continue in the forecasted period, due to a larger patient pool, better disease awareness, and favourable reimbursement policies.
Download the Primary Biliary Cholangitis Market Forecast Report to understand which factors are driving the Primary Biliary Cholangitis market @ Primary Biliary Cholangitis Market Trends [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The report provides detailed epidemiological data segmentation covering total diagnosed prevalent cases, gender-specific diagnosed prevalent cases, and age-specific diagnosed prevalent cases of primary biliary cholangitis across the 7MM during the study period (2020-2034).
According to the primary biliary cholangitis epidemiology contained in the report, the US accounted for the largest proportion of diagnosed prevalent PBC cases among the 7MM in 2023. Furthermore, the epidemiology model reveals a significantly higher prevalence among females compared to males across all markets, attributable to genetic predisposition, hormonal influences, and environmental factors. Among European nations, Germany reported the highest burden, followed by Italy and the UK. The data also indicates that PBC predominantly affects individuals aged 40-70 years, reinforcing the importance of age-targeted screening and treatment strategies.
Discover evolving trends in the Primary Biliary Cholangitis patient pool forecasts @ Primary Biliary Cholangitis Epidemiological Analysis [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The current primary biliary cholangitis treatment landscape has been historically dominated by ursodeoxycholic acid (UDCA) as the cornerstone first-line therapy, with obeticholic acid (OCALIVA) from Intercept Pharmaceuticals serving as the second-line option for patients with inadequate response to or intolerance of UDCA. However, the therapeutic paradigm has experienced significant evolution in 2024 with the FDA granting accelerated approvals to two novel treatments: Elafibranor (IQIRVO) in June 2024 by Genfit/Ipsen and Seladelpar (LIVDELZI) in August 2024 by Gilead Sciences. Both therapeutics represent innovative approaches targeting peroxisome proliferator-activated receptors, offering new mechanisms to address the complex primary biliary cholangitis pathophysiology.
The primary biliary cholangitis clinical trials market is demonstrating robust activity, with several promising candidates advancing through the development pipeline. Saroglitazar Magnesium by Zydus Therapeutics, a dual PPAR alpha/gamma agonist with the FDA Fast Track and Orphan Drug designations, shows substantial potential in addressing both cholestasis and metabolic aspects of PBC. A Phase IIb/III trial (NCT05133336) is ongoing to further evaluate its dual PPAR alpha/gamma agonism targeting metabolic and inflammatory pathways.
GlaxoSmithKline's Linerixibat, an IBAT inhibitor currently in Phase III trials, targets the debilitating pruritus associated with PBC. Additionally, COUR Pharmaceuticals' CNP-104 secured FDA Orphan Drug Designation in January 2025, positioning it as potentially the first disease-modifying treatment for PBC by inducing tolerance to pathogenic activated PDC-E2 T-cells that drive bile duct inflammation.
Discover evolving trends in the Primary Biliary Cholangitis treatment landscape @ Primary Biliary Cholangitis Recent Developments [https://www.delveinsight.com/sample-request/primary-biliary-cholongitis-pbc-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Despite these significant advancements, the PBC market faces several challenges, including insufficient disease awareness among healthcare providers and patients, complex diagnostic processes resulting in under-recognition, and affordability barriers to innovative treatments. Addressing these obstacles will require comprehensive educational initiatives, streamlined diagnostic pathways, and creative pricing strategies to improve treatment accessibility.
Furthermore, safety concerns continue to emerge, as evidenced by the FDA's recent identification of serious liver injury cases in non-cirrhotic PBC patients treated with obeticholic acid. This new safety concern was announced in a Drug Safety Communication in December 2024, following a review of postmarket clinical trial data, highlighting the ongoing need for vigilant safety monitoring of both established and emerging therapies.
The primary biliary cholangitis competitive landscape is evolving rapidly, with several key players actively involved in therapeutic development and commercialization. Some of the pharmaceutical companies active in this landscape include Gilead Sciences (NASDAQ: GILD), Intercept Pharmaceuticals (NASDAQ: ICPT), CymaBay Therapeutics (NASDAQ: CBAY), COUR Pharmaceuticals, Teva Pharmaceutical (NYSE: TEVA), Mylan, AbbVie (NYSE: ABBV), Glenmark Pharmaceuticals (NSE: GLENMARK), Allergan, Eli Lilly (NYSE: LLY), Novartis (NYSE: NVS), Pfizer (NYSE: PFE), Roche (SWX: ROG), Merck (NYSE: MRK), Bristol-Myers Squibb (NYSE: BMY), AstraZeneca (NASDAQ: AZN), GlaxoSmithKline (NYSE: GSK), Takeda (NYSE: TAK), Amgen (NASDAQ: AMGN), Boehringer Ingelheim, Dr. Reddy's (NYSE: RDY), Amneal (NASDAQ: AMRX), Alnylam (NASDAQ: ALNY), Ionis (NASDAQ: IONS), Arrowhead (NASDAQ: ARWR), CureVac (NASDAQ: CVAC), Sangamo (NASDAQ: SGMO), Calliditas Therapeutics (NASDAQ: CALT), NGM Biopharmaceuticals (NASDAQ: NGM), Bluebird Bio (NASDAQ: BLUE), Intellia (NASDAQ: NTLA), Albireo, TARGET PharmaSolutions, Genfit (NASDAQ: GNFT), and Ascletis Pharma, among others.
Looking ahead, DelveInsight forecasts the primary biliary cholangitis market will witness accelerated growth driven by the continued uptake of newly approved therapies and the potential introduction of pipeline candidates addressing unmet needs. The integration of biomarker-guided treatment approaches and combination regimens is anticipated to optimize therapeutic outcomes, while ongoing research into disease-modifying interventions may fundamentally transform the treatment paradigm. As the understanding of PBC pathophysiology advances, the market is poised for further innovation, with the ultimate goal of improving quality of life and long-term outcomes for patients living with this challenging autoimmune liver condition.
Table of Contents
1. Key Insights
2. Executive Summary of Primary Biliary Cholangitis
3. Primary Biliary Cholangitis Competitive Intelligence
4. Primary Biliary Cholangitis: Market Overview at a Glance
5. Primary Biliary Cholangitis: Disease Background and Overview
6. Patient Journey
7. Primary Biliary Cholangitis Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Biliary Cholangitis Unmet Needs
10. Key Endpoints of Primary Biliary Cholangitis Treatment
11. Primary Biliary Cholangitis Marketed Products
12. Primary Biliary Cholangitis Emerging Therapies
13. Primary Biliary Cholangitis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Primary Biliary Cholangitis
17. KOL Views
18. Primary Biliary Cholangitis Market Drivers
19. Primary Biliary Cholangitis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports
Primary Biliary Cholangitis Pipeline Insight [https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Primary Biliary Cholangitis Pipeline Insight provides comprehensive insights about the Primary Biliary Cholangitis pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Primary Biliary Cholangitis companies, including Zydus Therapeutics, Calliditas Therapeutics, Hepagene, Calliditas Therapeutics, Dr Falk Pharma, Mirum Pharmaceuticals, and GlaxoSmithKline, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-biliary-cholangitis-treatment-market-valued-at-usd-12-billion-in-2023-projected-to-grow-significantly-through-2034-driven-by-anticipated-pipeline-drugs-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Treatment Market Valued at USD 1.2 Billion in 2023; Projected to Grow Significantly Through 2034 Driven by Anticipated Pipeline Drugs | DelveInsight here
News-ID: 4008301 • Views: …
More Releases from ABNewswire
Gujarat Science City Celebrates World Penguin Day With Special Announcement And …
Gujarat Science City celebrates World Penguin Day with the historic birth of three African Penguin chicks-Daisy, Kiara, and Balloo-highlighting a milestone in marine conservation.
Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXe3Qizd7zO3GNJl2aqH5Nr1uY01bmVvCznFtQbKAtrmr9kClxxZXVzhxFulWHgA1m3ANSbStfJzi_1Ree_-dgdDyul6IG5uv1u9I3S9YM3yr91bzmJBtDAHB2WBndZL4LmLqak976YKEfbcPX35_w?key=x2GoGSCzW3f3Jo40rgl4mg
On the occasion of World Penguin Day, Gujarat Science City is delighted to celebrate a significant milestone - the successful in-house breeding of three African Penguin chicks at the Aquatic Gallery. This marks a historic achievement in the Gallery's ongoing commitment to conservation, education, and marine…
LegalCrystal Launches $0 Business Formation with Same-Day Filing in the USA
LegalCrystal now offers a $0 business formation with same-day filing in all 50 states. Included is a free 12-month Registered Agent service, without mandatory subscriptions, and with lifetime alerts. Clients pay only the required state fee. Fast, clear, and no hidden charges.
HOUSTON, TX - LegalCrystal [https://legalcrystal.com/] now offers zero-dollar business formation in all 50 U.S. states. The process includes same-day filing, a free 12-month Registered Agent service (normally $119), and…
Where Faith Meets Fire: A Thriller Unearths the Temple's Darkest Secrets
In the Shadow of the Temple - A Novel That Dares to Question Faith
ATLANTA, GA - Deep within the carved stone of sacred sanctuaries, beneath the chants and cloaks of ancient orders, lies a secret history never meant to be spoken. In his gripping novel, In the Shadow of the Temple: The Lucifer Principle [https://www.amazon.com/Shadow-Temple-Roy-Goodliffe/dp/1966088566/ref=tmm_pap_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9._j6MwNaQPJFoC2oLISqzAQ.pfZlmZoGoF__xzUFWwQvfCJYeN98SFwsbuTrSGHNJ8g&qid=1745623795&sr=1-1], author Roy Goodliffe drags it into the light.
Equal parts investigative thriller and historical expose, In…
Mind & Body Rejuvenation Clinic Offers Holistic Support in Temecula
Temecula, CA - Mind & Body Rejuvenation Clinic [https://mindbodyrejuvenationclinic.com/weight-loss-clinic-temecula/], located in the heart of Temecula, California, is proud to announce an expanded suite of services designed to support patients before, during, and after weight loss journeys-particularly those undergoing lap band or gastric bypass surgeries. With a rising number of individuals turning to surgical weight loss solutions, the clinic now offers a unique combination of services targeting both improved eating habits…
More Releases for Primary
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
Global Primary Sclerosing Cholangitis Market
The Primary Sclerosing Cholangitis report offers insights into vital aspects like growth,CAGR value, market share and revenue analysis. It evaluates the growth opportunities, threats, market drivers and risks involved. understand the market competition by analyzing the top vendors, with their market profile, revenue, profits, import-export details, and market share. it states the pricing structure, import-export details, supply chain analysis, SWOT analysis to facilitate the key decision-making process. This report helps…
Primary Lithium Battery (Primary Lithium Batteries) Industry Analysis by 2025: …
In its recently published report, QY Research has provided unique insights about global Primary Lithium Battery (Primary Lithium Batteries) market for the given period. One of the main objectives of this report is to categorize the various dynamics of the market and to offer latest updates such as mergers and acquisitions, various technological developments, new entrants in the market, which make an impact on different segments of the global Primary…
Primary Cells And Primary Batteries Market Analysis by Production Capacity, Dyna …
This report helps to analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Primary Cells And Primary Batteries market.
Description
The Global Primary Cells And Primary Batteries Market report offers a comprehensive evaluation of the Global Primary Cells And Primary Batteries industry. This report evaluates the Global market for " Global Primary Cells And Primary Batteries".
The Global Primary Cells…
Primary Immunodeficiency Diseases Market: Key Insights
With only a handful of companies enjoying the major share of the revenue pie, the global primary immunodeficiency diseases (PIDD) market exhibits a consolidated vendor landscape. As per Transparency Market Research (TMR), CSL Behring LLC and Grifols S.A. emerged dominant in the market with a share of 60.5% in 2014. Baxter International, Inc. and Octapharma AG are other prominent enterprises operating in the global PIDD market.
These companies have been…
Global Primary Biliary Cholangitis Treatment Market is Driven by Rise in Inciden …
Primary biliary cholangitis, previously known as primary biliary cirrhosis, is a rare chronic liver disease, primarily characterized by destruction of the bile ducts which transport bile acid out of the liver. Although the primary cause of the disease has not yet been elucidated, research across the world has attributed it to be autoimmune in nature. The progress of this disease results in the harmful accumulation of bile acid, which causes…
